Back to discover
Disease

Nausea

Late-stage therapeutic developmentEmerging researchSteady momentum
7
Publications
24
Clinical trials
3
Related conditions
1
Related treatments
1
Related proteins
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.

Research2025-02-01The New England journal of medicine

Safety of Semaglutide.

Research2021-07-07Frontiers in endocrinology

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Research2021-02-10The New England journal of medicine

Approval: Sancuso (EMA)

Regulatory2012-04-20EMA

Approval: Ivemend (EMA)

Regulatory2008-01-11EMA

Approval: Emend (EMA)

Regulatory2003-11-11EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical Milestones11View all 11
+3 more in the activity timeline below
Activity timeline11

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Palonosetronapproved

Approval — Palonosetron Accord is indicated in adults for: the prevention of acute nausea and vomit… (2016)

Granisetronapproved

Approval — Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic c… (2012)

Approval — Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer… (2008)

Aprepitantapproved

Approval — Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vom… (2003)

Research-associated treatments

Clinical trials

18 sponsors · 4 new · 6 completed in the last 12 months (net +4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2016emaApprovalPalonosetron· Palonosetron Accord is indicated in adults for: the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Palonosetron Accord is indicated in paediatric patients 1 month of age and older for: The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. source ↗
2012emaApprovalGranisetron· Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy. source ↗
2008emaApprovalFosaprepitant· Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy. source ↗
2003emaApprovalAprepitant· Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

7 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20142025
Major themes8
  • Antibodies, Bispecific1
  • Antidepressive Agents1
  • Antineoplastic Agents, Immunological1
  • Breast Neoplasms1
  • Immunoconjugates1
  • Nausea1
  • Neoplasms1
  • Neuregulin-11
Leading journals6
  • The New England journal of medicine2
  • Blood1
  • Frontiers in endocrinology1
  • JAMA1
  • Neurogastroenterology and motility1
  • The oncologist1
Leading researchers8
  • Adeyemi S1
  • Alesini D1
  • Ballatore Z1
  • Barberi V1
  • Batterham RL1
  • Bekaii-Saab T1
  • Botticelli A1
  • Burke JM1
Affiliations (unnormalised)6
  • "S. Carlo" Hospital1
  • "Sapienza" University of Rome1
  • Abramson Cancer Center1
  • AOU Policlinico Umberto I1
  • Central Hospital of Belcolle1
  • Chao Family Comprehensive Cancer Center1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Nausea is an unpleasant sensation in the stomach that is usually accompanied by an urge to vomit. It is a symptom rather than a disease entity and is commonly discussed in relation to physiopathology and therapy.

Causes

The supplied grounding identifies early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses as common causes of nausea. No additional causes are supported by the provided material.

Pathophysiology

The grounding supports nausea as a physiopathologic symptom, but it does not provide a detailed biological mechanism. It also notes co-study with trkB receptor and semaglutide, but no mechanism is described in the supplied abstracts that can be attributed specifically to nausea.

Risk factors

The provided material supports early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviral infections as factors associated with nausea. No broader risk-factor framework is supported beyond these common causes.

Current standard of care

The supplied review material supports cannabinoid-based therapies as being studied for nausea and vomiting due to chemotherapy, indicating cannabinoids as a treatment modality in that context. It also notes semaglutide as a co-studied drug in relation to gastrointestinal side effects, but does not support semaglutide as a treatment for nausea.

AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.